REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Objective: The purpose of this study was to examine the effects of REL-1017 (esmethadone), a novel N-methyl-d-aspartate receptor (NMDAR) channel blocker, in patients with major depressive disorder who failed to benefit from one to three standard antidepressant treatments in their current major depressive episode. Methods: A 7-day phase 2 multicenter randomized double-blind placebo-controlled trial, comprising three arms, was conducted to assess the safety, tolerability, pharmacokinetics, and efficacy of two dosages of REL-1017 (25 mg or 50 mg orally once a day). Patients were randomly assigned in a 1:1:1 ratio to placebo (N=22), REL-1017 25 mg/day (N=19), or REL-1017 50 mg/day (N=21). Safety scales included the 4-item Positive Symptom Rating Scale for psychotomimetic symptoms, the Clinician-Administered Dissociative States Scale for dissociative symptoms, the Clinical Opiate Withdrawal Scale for withdrawal signs and symptoms, and the Columbia-Suicide Severity Rating Scale for suicidality. The primary efficacy endpoint was the Montgomery‐Åsberg Depression Scale (MADRS) score. All 62 randomly assigned patients were included in the full analysis set population analysis. Results: Patients experienced mild or moderate transient adverse events and no evidence of dissociative or psychotomimetic effects, opioid effects, or withdrawal signs and symptoms. The improvement in MADRS score shown on day 4 in both of the REL-1017 dosage groups was sustained through day 7 (last dose) and day 14 (7 days after the last dose), with effect sizes from 0.7 to 1.0. Conclusions: This trial showed favorable safety, tolerability, and pharmacokinetic profiles and suggests that REL-1017 may have rapid and sustained antidepressant effects compared with placebo in patients with inadequate responses to antidepressant treatments. These results will need confirmation in larger and longer trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Esmethadone was found to reduce cognitive symptoms in individuals with MDD in a stage II clinical study 478”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [478]
In the citing paper
“Phase 2a, randomized, double-blind trials (n = 62 in both trials) found significant rapid and sustained (seven days) antidepressant effects in participants with TRD after repeated administration of REL-1017 [184,185]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [184]
In the citing paper
“Compared to placebo, subjects in both d-methadone treatment groups began showing meaningful improvements across depressive outcome measures by day four, which persisted for one week following the subjects’ last dosage [134].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [134]
In the citing paper
“A phase IIa RDBPCT evaluated the AD efficacy of one loading dose followed by daily oral d-methadone as an add-on to TRD patients’ existing therapies [134].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [134]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 28 · Cited by 83
Research works printed but not linked: 5
- Eddy NB, 1957, Bull World Health Organ, 17, 569
- Codd EE, 1995, J Pharmacol Exp Ther, 274, 1263
- Isbell H, 1948, J Pharmacol Exp Ther, 93, 305
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- Busner J, 2007, Psychiatry (Edgmont), 4, 28
Metadata
- Authors
- Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., de Somer, M., Caron, J., Vitolo, O. V., DiGuglielmo, G. R., Gilbert, A., Mehta, H., Kearney, M., Mattarei, A., Gentilucci, M., Folli, F., Traversa, S., Inturrisi, C. E., & Manfredi, P. L.
- Affiliations
- Department of Psychiatry, Massachusetts General Hospital, Boston (Fava, Vitolo); Neuroscience Education Institute, University of California, San Diego (Stahl); Department of Psychiatry and Behavioral Sciences, University of Miami School of Medicine, Miami (Pani); Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy (Martin, Mattarei); Department of Anesthesiology, Albert Einstein College of Medicine, Bronx, N.Y. (Pappagallo); University of Genoa, Genoa, Italy ...
- Albert Einstein College of Medicine (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2022-02
- Volume
- 179
- Issue
- 2
- Pages
- 122-131
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W4200195182
- Cited by
- 83
- References
- 28
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 18 · 2023: 22 · 2022: 21
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- major depressive disorder, NMDA receptor antagonists, adjunctive antidepressant therapy, treatment-resistant depression, antidepressant efficacy, drug safety and tolerability, pharmacokinetics, dissociative symptoms, psychotomimetic effects, opioid withdrawal
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Humans, Treatment Outcome, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2021.21020197
- The paper
- Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., de Somer, M., Caron, J., Vitolo, O. V., DiGuglielmo, G. R., Gilbert, A., Mehta, H., Kearney, M., Mattarei, A., Gentilucci, M., . . . Manfredi, P. L. (2022). REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2021.21020197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.